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AbstrAct
Previous studies showed that YAP1 is over-expressed in hepatocellular carcinoma 
(HCC). Here we observed higher expression of Yap1/Ctgf axis in dysplastic nodules and 
HCC chemically-induced in F344 rats, genetically susceptible to hepatocarcinogenesis, 
than in lesions induced in resistant BN rats. In BN rats, highest increase in Yap1-
tyr357, p73 phosphorylation and Caspase 3 cleavage occurred. In human HCCs with 
poorer prognosis (< 3 years survival after partial liver resection, HCCP), levels of 
YAP1, CTGF, 14–3–3, and TEAD proteins, and YAP1-14-3-3 and YAP1-TEAD complexes 
were higher than in HCCs with better outcome (> 3 years survival; HCCB). In the 
latter, higher levels of phosphorylated YAP1-ser127, YAP1-tyr357 and p73, YAP1 
ubiquitination, and Caspase 3 cleavage occurred. Expression of stemness markers 
NANOG, OCT-3/4, and CD133 were highest in HCCP and correlated with YAP1 and 
YAP1-TEAD levels. In HepG2, Huh7, and Hep3B cells, forced YAP1 over-expression 
led to stem cell markers expression and increased cell viability, whereas inhibition 
of YAP1 expression by specific siRNA, or transfection of mutant YAP1 which does 
not bind to TEAD, induced opposite alterations. These changes were associated, in 
Huh7 cells transfected with YAP1 or YAP1 siRNA, with stimulation or inhibition of cell 
migration and invasivity, respectively. Furthermore, transcriptome analysis showed 
that YAP1 transfection in Huh7 cells induces over-expression of genes involved 
in tumor stemness. In conclusion, Yap1 post-translational modifications favoring 
its ubiquitination and apoptosis characterize HCC with better prognosis, whereas 
conditions favoring the formation of YAP1-TEAD complexes are associated with 
aggressiveness and acquisition of stemness features by HCC cells.
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INtrODUctION
Hepatocellular carcinoma (HCC) is a frequent 
and fatal human cancer [1, 2]. Previous work in our 
laboratory, has shown highest over-expression of iNOS/
NF-kB (inducible nitric oxide synthase/nuclear factor-kB), 
RAS/ERK (extracellular signal-regulated kinase), FoxM1 
(Forkhead box M1B), Mybl2 (v-Myb avian myeloblastosis 
viral oncogene homolog-like2), and decrease in 
methionine metabolism, in the human HCC subtype 
with poorer prognosis (< 3 years survival, after partial 
liver resection, HCCP), and low/absent in the human 
HCC subtype characterized by better outcome (> 3 years 
survival; HCCB) [1].  Interestingly, utmost upregulation 
of above signaling pathways in rapidly progressing HCC 
chemically induced in Fisher 344 (F344) rats, genetically 
susceptible to hepatocarcinogenesis, contrasts with low/
absent deregulation of the same cascades in slowly 
progressing lesions of genetically resistant Brown Norway 
(BN) rats, suggesting a genetic control of signaling 
deregulation and HCC aggressivity [2]. 
Recent studies indicate the deregulation of 
Hippo/YAP signaling in oval cells and HCC [1, 3, 4]. 
A complex network of not yet completely known 
mechanisms regulates this pathway. Some inputs are 
associated with plasma membrane and might transmit 
information from the extracellular milieu or cell-cell 
contacts [1, 5]. MST1/2 (homologues of Hpo), MOB1A/B 
(preimplantation protein 1, mouse, homolog of), and 
LATS1/2 (Wts homologues) are involved in YAP (Yes 
kinase-associated protein) phosphorylation (Figure 1). 
YAP1 phosphorylation at ser127 residue allows 14-3-3 
binding and cytoplasmic sequestration and inactivation, 
whereas phosphorylation at tyr357 promotes YAP1 nuclear 
translocation and binding to the oncosuppressor p73 
[1, 5]. Moreover, phosphorylation at ser381 by LATS1/2 
primes YAP for subsequent phosphorylation at ser384 
and ser387, presumably by casein kinase-1 (CK1δ/ε), 
allowing the recruitment to YAP of E3 ubiquitin ligase 
SCFβ-TRCP (Skp1-Cullin1-F-box protein beta-transducin 
repeat-containing protein) followed by YAP ubiquitination 
and proteolysis [5]. Finally, nuclear migration of not 
phosphorylated YAP protein is followed by the formation 
of YAP/TEAD complex that enhances cell proliferation 
and inhibits apoptosis [1, 5]. 
Cumulating observations indicate that the Hippo/
YAP signaling is critical for HCC development [6, 7]. 
Connective tissue growth factor (CTGF) expression can be 
stimulated through the Amphiregulin (AREG)-(Epidermal 
growth factor receptor) EGFR-cascade in a crosstalk 
with YAP in HCC cells [7]. YAP inhibition is able to 
restore hepatocyte differentiation in advanced HCC [8]. 
Furthermore, recent results provide immunohistochemical 
evidence of Yap overexpression in carcinogen-induced 
early liver preneoplastic lesions and HCC of rats and 
human HCC [9]. Verteporfin, an inhibitor of Yap-Tead 
complex, reduced oval cell proliferation and preneoplastic 
and neoplastic lesions development in the rat liver 
[9]. In accordance with the latter findings, activation 
of YAP due to the loss of the YAP inhibitor, WW45, 
leads to unrestrained hepatic oval cell proliferation and 
oval cell-driven tumor development in mice [10]. The 
latter findings envisage a critical role of the Hippo/YAP 
signaling in stem cell proliferation/expansion. Moreover, 
YAP overexpression occurs most often in HCCs and 
combined Cholangiocarcinoma-HCCs displaying stemness 
markers [11]. Importantly, recent observations suggest 
the implication of stem cells in HCC aggressiveness and 
recurrence [12]. 
Although the aforementioned data convincingly 
indicate that YAP is oncogenic in liver cancer, other 
findings support an oncosuppressor effect of YAP in 
cancer. Indeed, YAP is able to inhibit the growth of 
human malignant cells by activating apoptogenic p73 
pathway [13], the PML (Promyelomonocytic leukemia) 
oncosuppressor protein interacts with YAP1, enhancing its 
stabilization [14], and YAP increases chemosensitivity of 
HCC cells by modulating p53 [15]. YAP also suppresses 
head and neck [16] and breast [17] cancers.
Recent findings showed that TAZ (Transcriptional 
co-activator with PDZ-binding motif), another 
downstream effector of the Hippo signaling pathway, but 
not YAP, is predominantly expressed in HCC. In the same 
sample collection, nonetheless, YAP overexpression was 
associated with HCC poor prognosis, and a compensatory 
YAP upregulation following TAZ depletion conferred 
cancer stem cell-like properties to HCC cells [18].
We hypothesized that variations of YAP1 role in 
HCC growth and stemness might depend on differences 
in its post-translational deregulation. We tested this 
hypothesis by analyzing the relationship of post-
translational deregulation of YAP1, in prognostic subtypes 
of HCC, with the genetic predisposition to the disease and 
the activity of stemness key genes. We also analyzed the 
mechanism involved in the upregulation of these genes 
by YAP1.
rEsULts 
YAP/ctGF pathway is under genetic control in 
rat Hcc
Six weeks after initiation, foci of altered hepatocytes 
(mostly clear/eosinophilic cell lesions) occupied 76– 82% 
of the liver in F344 and BN rats. At 15–32 weeks, 
relatively few nodules were present in BN rat liver and 
nodule volume was much lower in BN than F344 rats 
(cm3: 0.032–0.11 and 0.11–0.52 in BN and F344 rats, 
respectively). Histologic analysis of pooled nodules 
showed that at 15 weeks all dysplastic nodules of both 
rat strains were low-grade lesions, whereas at 32 weeks 
low-grade and high-grade dysplastic nodules were 
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present in BN and F344 rats, respectively (Figure 2). 
Poorly differentiated and moderately differentiated HCCs 
developed at 57 weeks in F344 rats, whereas 90% well 
differentiated HCC developed at 60 weeks in BN rats 
(Figure 2). 
Quantitative RT-PCR (QRT-PCR) analysis showed 
the absence of differences of Yap1 and Ctgf expression 
between normal livers from F344 and BN rats, whereas 
mRNAs levels of both genes were significantly higher in 
preneoplastic liver, dysplastic nodules and HCCs of F344 
than BN rats (Figure 3A). Yap1 and Ctgf protein levels 
sharply increased in F344 rat lesions, compared to normal 
liver, whereas no changes/lower increase occurred in 
BN rats (Figure 3B, 3C). These findings were associated 
with a sharp decrease in phosphorylated Yap1-ser127 and 
increase in phosphorylated Yap1-tyr357 in HCC of both 
Figure 1: schematic representation of HIPPO/YAP pathway. The upstream activators of MST1/2 are not defined although cell–
cell contact probably is an important stimulus. RASSF family proteins could link MST1/2 to extracellular signals facilitating their activation 
before the proteolytic cleavage. Indeed, most catalytically active MST1/2 in the liver are in a truncated form that lacks the autoregulatory 
carboxy-terminus. Mst1/2 are required to phosphorylate MOB1. Phospho-MOB1 is likely to facilitate the activation of an intermediary 
kinase, which phosphorylates YAP. YAP phosphorylation at ser127 allows 14-3-3 binding and cytoplasmic sequestration. Subsequent 
phosphorylation of YAP-ser127 at ser381 by LATS1/2 followed by phosphorylation at ser384 and ser387 by CK1δε allows ubiquitinylation 
and degradation. The phosphorylation of YAP at tyr357 promotes nuclear translocation and binding to the oncosuppressor p73. Nuclear 
migration of not phosphorylated YAP protein is followed by the formation of YAP/TEAD complex that enhances cell proliferation and 
inhibits apoptosis.
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rat strains, with respect to normal liver, with lowest values 
of pYap1-ser127 in F344 HCC and highest values of pYap1-
tyr357 in BN HCC, respectively (Figure 3D, 3E). A significant 
rise of Yap1 ubiquitination occurred only in BN HCC, and 
p73 phosphorylation increased in HCC of both strains, with 
highest values in BN rats (Figure 3D, 3E). Accordingly, HCC 
of both strains exhibited a significant increase in Caspase 3 
cleavage [expressed as fall in the 36/(19+17) kD ratio], taken 
as a measure of apoptosis, compared to normal liver, which 
was 4-fold higher in BN than F344 rats (Figure 3F, 3G).
YAP1 post-translational changes in human Hcc 
prognostic subgroups
Above results suggest a link between the genetic 
predisposition to HCC and the deregulation of YAP1 
signaling, and envisage a role of the latter in HCC 
aggressiveness. This prompted us to analyze YAP1 expression 
and post-translational regulation in human HCCs with 
different growth rate and propensity to progress. Two groups 
of 20 patients with HCCB and HCCP were used for these 
experiments (Table 1). No significant differences between 
the two groups occurred as concerns patients’ sex, etiology, 
presence of cirrhotic liver, and Edmondson-Steiner grade. 
Significantly higher tumor size, alpha-fetoprotein secretion, 
proliferation index (Ki67 expression), YAP1 expression, and 
Midkine expression (as index of poor differentiation), [19, 
20], were found in HCCP than in HCCB.
The evaluation of the AREG/EGFR/YAP/CTGF 
axis in human HCC subgroups showed an increase of 
AREG, EGFR, YAP and CTGF mRNA expression, with 
respect to normal liver, which was progressively higher 
from SLB, HCCB, SLP to HCCP (Figure 4A). Western 
blot analysis (Figure 4B, 4C) showed progressive 
increase of YAP1 and CTGF proteins from HCCB to 
SLP, and HCCP. Phosphorylated YAP1-ser127 decreased 
in SL and HCC, with lowest values in HCCP. However, 
14-3-3 protein and YAP1-14-3-3 complex increased 
in SL and HCC, with highest values in HCCP. YAP1 
ubiquitinylation progressively decreased from HCCB to 
SLP and HCCP, lowest values were observed in HCCP. 
TEAD protein and YAP1-TEAD complex showed small 
increase/no change in SLs and highest increase in HCCP 
(Figure 4B, 4C). These results indicate that YAP1 post-
translational regulation supports HCC progression by 
favoring the formation of YAP1-TEAD complex. The 
relationships between YAP1 protein and YAP1-TEAD 
complex levels and HCC progression were confirmed by 
their significant correlation with CTGF, Ki67, and MDK 
protein expression (Figure 5).  
Figure 4 also shows that phosphorylated YAP1-
tyr357 increased with respect to normal liver in 
surrounding liver and HCC, with highest values in HCCB. 
YAP1-tyr357 is a stable protein that enters the nucleus, 
displays high affinity to p73, and selectively co-activates, 
together with p73, proapoptotic genes [21]. Thus, the 
Figure 2: Preneoplastic and neoplastic liver lesion of F344 and bN rats. (A) low-grade dysplastic nodule of BN rats. (b and c) 
high-grade dysplastic nodules of F344 rats. (A’) well-differentiated HCC of BN rats.  (b’ and c’) moderately differentiated and poorly 
differentiated HCC, respectively, of F344 rats. Low-grade dysplastic nodules were constituted prevalently by eosinophilic hepatocytes. 
High-grade nodules exhibited prevalently small hepatocytes with high nuclear:cytoplasmic ratio, hepatocytes in nests or pseudo-gland 
formation, and cytoplasmic basophilia. Initial magnification: A–C,  A’, B’, 200×; C’, 400×.
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Figure 3: Expression and post-translational modifications of YAP1 in preneoplastic and neoplastic rat liver lesions 
induced in rats by ‘‘resistant hepatocyte’’ protocol. (A) mRNA levels of Yap and Ctgf, determined by QRT-PC, in normal liver 
(NL), pre-neoplastic liver (4–6 weeks after initiation, PL), early nodules (15 weeks, EN), late nodules (32 weeks, LN), and HCCs. N Target 
(NT) = 2-ΔCt; ΔCt = Ct RNR18S-Ct target gene. (b) Representative Western blots of Yap1 and Ctgf proteins. (c) Chemiluminescence 
analysis: optical densities were normalized to β-actin levels and expressed in arbitrary units. (D) Representative Western blots of YAP 
phosphorylated at ser127 and tyr357, YAP ubiquitinated, and phosphorylated p73. (E) Chemiluminescence analysis: optical densities were 
normalized to β-actin levels and expressed in arbitrary units. Data are means (SD) of 4–10 rats. Tukey-Kramer test: Point, different from NL 
for at least P < 0.02. Asterisk, F344 different from BN for at least P < 0.01. (F) Representative Western blot and (G) Chemiluminescence 
analysis showing means (SD) of 5 experiments of Caspase 3 cleavage. in NL and HCC of F344 (F) and BN (B) rats. Optical densities 
of the peaks were normalized to β-actin levels and expressed in arbitrary units. Tukey-Kramer test: Point, different from NL for at least 
P < 0.0001. Asterisk, F344 different from BN for at least P < 0.0001. 
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evaluation of the nuclear localization of phosphorylated 
YAP1-tyr357 in the different subtypes of HCC and 
correspondent SLs may give further insights on the 
effects of YAP1 post-translational deregulation in HCC. 
Figure 6A, 6B shows that the percentage of cells showing 
pYAP1-tyr357 immunoreactivity progressively decreased 
from HCCB to SLP and HCCP. HCCB also showed the 
highest nuclear localization of pYAP1-tyr357, whereas 
this localization was much lower in HCCP and was 
scanty in SLB and SLP. Accordingly, apoptosis (caspase 
3 cleavage expressed as decrease in 36/19 kD ratio) was 
about 2-fold lower in HCCP than HCCB, whereas in SLs 
it did not significantly differ from that found in normal 
liver.
YAP1 role in stem cell likeness of liver cancer
The aforementioned data envisage a connection 
of YAP1 post-translational regulation and YAP1-TEAD 
complex level with HCC aggressiveness. YAP-TEAD 
signaling was previously shown to activate the promoters 
of OCT-3/4 and NANOG stem cell markers [22], and 
recent results [18] showed overexpression of CD90, 
a cancer stem cell marker, in HCC cell lines in which 
YAP1 expression was stimulated as a consequence of 
TAZ inhibition. We thus examined the role of YAP1 
in expression of stem cell markers in HCC prognostic 
subgroups. Figure 7A shows significant increases in stem 
cell markers CD133, NANOG, and OCT-3/4 mRNA levels 
table 1: clinicopathological features of Hcc patients
Hccb HccP
No. of patients
   Male
   Female
   11
     9
  13
    7
Age (Mean ± SD)    63.4 ± 12.8   67.2 ± 8.9
Etiology
   HBV
   HCV
   Ethanol    
   14
     4
     2 
  17
    3
    0
Cirrhosis
   +
   –
   18
     2
   17
     3
Tumor sizea
   > 5 cm
   < 5 cm
     7
   13
   15
     5
Edmondson and Steiner grade
I
II
III
IV
     1
   12
     7
     0
     0
     8
   10
     2
Alpha-fetoprotein secretionb
    > 300 ng/ml of serum
    < 300 ng/ml of serum
      8
    12
   17
     3
Proliferation index (× 103)c       7.2 ± 1.3    14.9 ± 2.7
YAP1 expression (× 103)d       2.8 ± 0.9      5.8 ± 1.2
Midkine expression (× 103)e       1.1 ± 1.0    47.9 ± 34.8
Survival after partial liver resection (months). Mean ± SDf       54 ± 12.2    22 ± 8.3
HCCB, HCC with better prognosis (survival > 3 years); HCCP, 
HCC with poorer prognosis (survival < 3 years).
aFisher Exact Test. p = 0.025.
bFisher Exact Test: p = 0.008.
cKi67 expression (quantitative RT-PCR. 2-ΔCt; ΔCt = Ct RNR18-Ct
target gene): p < 0.0001.
dQRT-PCR. 2-ΔCt; ΔCt = Ct RNR18-Ct target gene: p < 0.001.
eQRT-PCR. 2-ΔCt; ΔCt = Ct RNR18-Ct target gene: p < 0.0005.
fp < 0.0001.
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Figure 4: Expression of AREG/EGFR/YAP/CTGF pathway and post-translational modifications of YAP1 in human 
normal liver (NL), Hcc, and corresponding surrounding liver (sL). HCCs were divided in two distinct categories based on 
the length of patient survival after partial liver resection: HCC with better outcome (survival > 3 years; HCCB), and HCC with poorer 
outcome (survival < 3 years; HCCP). (A) mRNA levels of AREG, EGFR, YAP1, and CTGF genes were determined by QRT-PCR. N 
Target (NT) = 2-ΔCt; ΔCt = Ct RNR18-Ct target gene. Data are means (SD) of NT of 5 normal livers (NL) and 20 of each HCC subtypes 
and corresponding SL. Mann-Whitney test: Point, different from NL for P < 0.001. Asterisk, different from SL for at least P < 0.01. 
Dagger, HCCP/SLP different from HCCB/SLB for P < 0.001. (b) Representative Western blots of Yap1, CTGF and phosporylated and 
ubiquitinylated YAP1, phosphorylated p73, 14-3-3, TEAD, and YAP1-14-3-3 and YAP1-TEAD complexes in NL, HCCB, HCCP and 
corresponding SL. (c) Chemiluminescence analysis: optical densities were normalized to β-actin levels and expressed in arbitrary units. 
Data are means (SD) of 5–20 experiments. Mann-Whitney test: Point, different from NL for at least P < 0.01. Asterisk, different from SL 
for at least P < 0.01. Dagger, HCCP/SLP different from HCCB/SLB for at least P < 0.01.
Oncotarget49201www.impactjournals.com/oncotarget
in HCCs and, at a lower extent, in the correspondent SLs, 
with respect to control, with highest values in HCCP. 
These results were partially confirmed by Western 
analysis, which showed progressive increase of NANOG 
and OCT-3/4 proteins from SL to HCC, and greatest 
values in HCCP (Figure 7B, 7C). Moreover, NANOG and 
OCT-3/4 protein levels were significantly correlated with 
YAP1 and YAP1-TEAD levels in HCC (Figure 7D).
Functional experiments using Hep3B and Huh7 
HCC cell lines and HepG2 hepatoblastoma cell line 
(Figure 8) showed that forced YAP1 overexpression was 
associated with a significant increase in the viability and 
mRNA levels of the stem cell markers CD133, NANOG, 
and OCT-3/4 in the three cell lines. In contrast, sharp 
decline of YAP1 expression by a specific siRNA led to 
a decrease in cell viability associated with a significant 
restraint of CD133, NANOG, and OCT-3/4 expression 
(Figure 9). These results were confirmed, at protein level, 
in Hep3B cells: NANOG underwent sharp decrease 
in cells treated with anti-YAP1 siRNA and significant 
increase consequent to forced YAP1 overexpression 
(Figure 10A, 10B). Furthermore, YAP1 transfection 
protected significantly Huh7 and HepG2 cell lines from 
apoptosis induced by 200 and 400 μM H2O2, although 
the higher H2O2 concentration inhibited by 50–60% YAP1 
expression (Figures 1 and 2). Very low/no protection from 
apoptosis, induced by 200 μM H2O2, occurred in the cells 
transfected with mutant YAP1 (Supplementary Figure 1 
and Figure 11).
The modulation of YAP1 levels strongly influenced 
in vitro migration and invasivity of Huh7 cells. Indeed, 
YAP1 overexpression resulted in enhanced cell migration 
in vitro that, differently from the cells transfected with 
the empty vector, led to almost complete reconstitution 
of the cell monolayer  36 h after the wound was generated 
in confluent cells. In contrast, the monolayer was not 
completely reconstituted even 48 h after wounding in cells 
treated with YAP1 siRNA (Supplementary Figure 2). Cell 
invasivity test revealed that forced YAP1 overexpression 
was associated with a 2-fold increase in cell invasion 
through polycarbonate membrane, whereas inhibition of 
YAP1 expression led to an about 5-fold decrease in cell 
invasion (Supplementary Figure 3).
Previously, it has been shown that TEAD mediates 
YAP-effect on gene induction and growth [23]. In order 
to demonstrate the involvement of YAP1-TEAD complex 
in the activation of stem cell markers in liver cancer cells, 
we evaluated the effect of verteporfin, which was reported 
to impede the YAP1-TEAD complex formation [24] and 
does not inhibit, at low doses, basal YAP expression 
[25]. In accordance with previous data, we found that 
the addition of 0.5 and 2 μM verteporfin to HepG2 
cells (Figure 12) did not significantly alter the basal 
mRNA and protein levels of all genes tested. However, 
Figure 5: correlation of YAP1 and YAP1-tEAD complex with ctGF, Ki67, and MDK (Midkine) in human Hccs. 
A total of 18 cases (9 HCCB and 9 HCCP) were used for the Spearman’s correlation analysis of YAP1, and a total of 15 cases (7 HCCB and 
8 HCCP) were used for the correlation analysis of YAP1-TEAD complex. 
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verteporfin inhibited the increase in YAP1 mRNA and 
protein levels and YAP1-TEAD complex level in YAP1 
transfected cells, without modifying TEAD levels, and 
was associated with relatively low/no increases in CTGF, 
NANOG, OCT-3/4, and CD133 mRNA and protein levels 
(Figure 12A–12C). Although these observations confirm 
a link between YAP1 upregulation and stem cell marker 
overexpression, they do not exclude the toxicity of even 
low verteporfin doses on YAP1 expression, which could 
hamper to evaluate the actual role of the decrease in 
YAP-TEAD complex. To rule out this possibility, HepG2 
cells were transfected with mutated YAP1 (YAP-S94A/
S127A; Figure 12D–12F), which does not form complex 
with TEAD [23]. No significant increases in mRNA and 
proteins levels of CTGF and stem cell markers occurred 
in these conditions.
Figure 6: pYAP-tys357 expression and caspase 3 cleavage in human Hcc and corresponding surounding liver. (A) 
Representative imaging of IHC staining of pYAP-tyr357 in HCCB and HCCP and SLs (100× and 400×). (b) Quantification of pYAP-tyr357 
IHC staining: The IHC quantification was evaluated according to the percentage of cells with positive cytoplasms and/or nuclei (upper 
panel) or cells with positive nuclei (lower panel). Data are means (SD) of 3 different HCC and SL subtypes.  Mann-Whitney test: Asterisk, 
HCC different from SL for at least P < 0.05. Dagger, HCCP/SLP different from HCCB/SL for P < 0.001. (c) Representative Western blots 
of Caspase 3 cleavage. (D) Chemiluminescence analysis: optical densities were normalized to β-actin levels and expressed in arbitrary 
units. Data are means (SD) of 5 experiments. Mann-Whitney test: Point, different from NL for P < 0.001. Asterisk, different from SL for 
P < 0.001. Dagger, HCCP/SLP different from HCCB/SLB for P < 0.001.
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YAP1 overexpression induces the expression of 
genes putatively involved in cancer stemness 
To further determine the cellular signaling 
network activated by YAP1 in HCC, gene expression 
profile analysis was carried out in four independent 
YAP1-transfected Huh7 cell cultures and four cultures 
transfected with empty vector. Cluster analysis of 136 
gene features showing more than 1.5-fold difference 
compared to median expression value in 4 arrays, revealed 
two distinctive gene expression patterns, the first of 
which included Huh7 cells transfected with empty vector, 
and the other YAP1 transfected cells (Figure 13). Data 
analysis using high statistical stringency revealed that 
the expression of 43 genes significantly differed between 
transfected cells and their controls (Table 2). Genes 
Figure 7: Expression of CD133, NANOG and OCT3-3/4 in human NL, Hccb, HccP, and corresponding sL. 
(A) mRNA levels were determined by QRT-PCR. N Target (NT) = 2-ΔCt; ΔCt = Ct RNR18-Ct target gene. Data are means (SD) of NT of 5 
NL and 20 of each HCC subtypes and SL. Mann-Whitney test: Point, different from NL for P < 0.001. Asterisk, different from SL for at 
least P < 0.01. Dagger, HCCP/SLP different from HCCB/SLB for P < 0.001. (b) Representative Western blots of NANOG and OCT-3/4. 
(c) Chemiluminescence analysis showing means (SD) of 5–15 experiments. Optical densities of the peaks were normalized to β-actin 
levels and expressed in arbitrary units. Mann-Whitney test: Point, different from NL for P < 0.001. Asterisk, different from SL for at least 
P < 0.05. Dagger, HCCP/SLP different from HCCB/SLB for at least P < 0.01. (D) Correlation of NANOG and OCT-3/4 levels with YAP1 
and YAP1-TEAD complex in human HCCs. A total of 30 cases (15 HCCB and 15 HCCP) and a total of 15 cases (7 HCCB and 8 HCCP) 
were used for the Spearman’s correlation analysis of YAP1 and YAP1-TEAD complex, respectively.  
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Table 2: Deregulated genes in Hep3B cells upon YAP forced overexpression identified by microarray 
analysis1
Gene symbol Description Log-ratio ParametricP value
Up-regulated  genes
Signal transduction
CTGF* connective tissue growth factor 0.7628 0.0064
NARG2* N-methyl-D-aspartate receptor regulated 2  0.5586 0.0183
MAP2K5* § mitogen-activated protein kinase kinase 5 11’199 0.0000
SPSB1* § SPRY domain-containing SOCS box protein 1 0.6239 0.0025
SFSR10* splicing factor, arginine/serine-rich 10 (transformer 2 homolog, Drosophila) 0.4996 0.0021
PPM1A* § protein phosphatase 1A, magnesium-dependent 0.3134 0.0357
PTPN11* § protein tyrosine phosphatase, non-receptor type 11 0.3143 0.0155
PTPRM § protein tyrosine phosphatase, receptor type, M 0.7708 0.0057
PEX14* peroxisomal biogenesis factor 14 0.5018 0.0292
PDE2A* § phosphodiesterase 2A, cGMP-stimulated 19’609 0.0000
Cell proliferation
CAPRIN1* cell cycle associated protein 1 0.3910 0.0011
CEP55 centrosomal protein 55 kDa 0.6724 0.0040
CSPP1* centrosome and spindle pole associated protein 1 0.3407 0.0127
LGALS7 lectin, galactoside-binding, soluble, 7 (galectin 7) 0.4825 0.0412
IL1A interleukin 1, alpha 0.4008 0.0018
CSRP1 cysteine and glycine-rich protein 1 0.3151 0.0211
IRF2 § interferon regulatory factor 2 0.6768 0.0342
Metabolism
LDHA § lactate dehydrogenase A 0.2179 0.0492
AADACL1* arylacetamide deacetylase-like 1 0.3646 0.0006
HGSNAT* heparan-alpha-glucosaminide N-acetyltransferase 0.5291 0.0253
MCCC1 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) 0.4430 0.0013
Varia
RBM35B* RNA binding motif protein 35B  0.4840  0.0029
RTTN rotatin  0.3821  0.0183
SH3KBP1 § SH3-domain kinase binding protein 1  0.4996  0.0021
CTDSPL2* carboxy-terminal domain small phosphatase like 2  0.5825  0.0079
NUP155 nucleoporin 155 kDa  0.4724  0.0447
Down-regulated genes
Signal transduction
CCM2* cerebral cavernous malformation 2 –0.5444 0.0018
CDC42SE2 CDC42 small effector 2 –0.7453 0.0019
ACTR5 ARP5 actin-related protein 5 homolog (yeast) –0.4928 0.0012
HHIP hedgehog interacting protein negative regulation of –0.4907 0.0014
MYBL1 v-myb myeloblastosis viral oncogene homolog (avian)-like 1 –0.6037 0.0160
TLE3* transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) –0.4688 0.0406
RAB4A RAD9 homolog B (S. cerevisiae) protein transport, small GTPase mediated signal transduction –0.3416 0.0095
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activated, in YAP1-transfected cells, were involved in 
signal transduction and cell proliferation (CTGF, NARG2, 
MAP2K5, SPSB1, SFSR10, PDE2A, PTPN11, PTPRM, 
PEX14, CAPRIN 1, CEP5S, CSPP1, LGALS7, IL1A), 
and cell metabolism (LDHA, AADACL1). Genes inhibited 
(Table 2) included genes involved in signal transduction 
(CFM2, CDC42SE2, HHIP) and metabolism (ALG3, 
PDHA2). To test the behavior of genes whose expression 
was influenced by changes in YAP1 expression in vivo, 
the levels of MAP2K5, PTPN11, SPB1, and PPM1A 
mRNA were determined in HCC prognostic subgroups. 
A significant increase in expression of these four genes 
occurred in HCC with respect to normal liver, with highest 
values in HCCP (Figure 14A). The occurrence of a link 
between YAP1 and MAP2K5, PTPN11, SPB1, and PPM1A 
expression was confirmed by the observation that forced 
YAP1 expression in HepG2 cells led to a 3–3.7 fold rise in 
their mRNA levels (Figure 14B). 
DIscUssION
YAP1 overexpression was suggested to be an 
independent prognostic marker for HCC [4, 26]. In line 
with these findings, our results show that the upregulation 
of the AREG/EGFR/YAP1/CTGF pathway is linked to 
HCC prognosis. Further, our data clearly indicate, for the 
first time, that the effects of YAP1 overexpression on HCC 
prognosis are largely influenced by differences in YAP1 
post-translational deregulation. Indeed, higher YAP1 
phosphorylation at ser127 and its ubiquitination, probably 
preceded by further phosphorylation of YAP1-ser127 [4, 5, 
27], occurred in HCCB, as compared to HCCP. Moreover, 
HCCB mainly exhibited YAP1 phosphorylation at ser357, 
which is associated with its nuclear translocation followed 
by p73 activation, and apoptosis [4, 5, 22, 26]. This could 
contribute to the better prognosis of this HCC subgroup. In 
contrast, lower phosphorylation at ser127 was prevalently 
associated with the formation of the cytoplasmic YAP1-
14-3-3 complex, while the presence of elevated levels 
of YAP1-TEAD complex indicated a consistent nuclear 
translocation of unphosphorylated YAP1, in HCCP. The 
YAP1-TEAD complex activates numerous growth-related 
genes in HCC [27]. Accordingly, we found a significant 
positive correlation of YAP1 and YAP1-TEAD levels with 
the expression of the proliferation marker Ki67, and the 
progression markers CTGF [28, 29] and MDK [19, 20], 
in HCC. 
Our results confirm previous observation that 
YAP1 over-expression is an early event in rat liver 
carcinogenesis [9]. They also show higher YAP1 
expression in preneoplastic and neoplastic lesions of F344 
rats, genetically susceptible to hepatocarcinogenesis, 
compared to resistant BN rats. Previous work in our 
laboratory [2] demonstrated that, similarly to the 
development of human HCC [30], the development of 
rat preneoplastic and neoplastic liver is under control of 
low-penetrance cancer modifier genes. Present results 
indicate that YAP1 post-translational deregulation 
favoring its ubiquitination, activation of p73, and 
apoptosis, is significantly higher in well-differentiated 
and slow-growing HCC of the genetically resistant BN 
strain, whereas YAP1 post-translational regulation seems 
to favor HCC fast growth in susceptible F344 rats.  This 
suggests that YAP1 post-translational deregulation is 
under control of HCC modifier genes, which could 
contribute to determine the relative amounts of YAP1 
triggering HCC growth and progression, and the amounts 
designed to be ubiquitinylated or to activate apoptogenic 
mechanisms. The similarity of the YAP1 post-translational 
deregulation in human and rat HCC, and of the genetic 
model regulating hepatocarcinogenesis in human and rat 
[2], suggests that YAP1 post-translational deregulation is 
under an analogous genetic control mechanism in both 
species.
Metabolism
ALG3* asparagine-linked glycosylation 3 homolog (S. cerevisiae, alpha-1,3-mannosyltransferase) –0.3714 0.0188
PDHA2 pyruvate dehydrogenase (lipoamide) alpha 2 –0.4227 0.0101
PRSS7 protease, serine, 7 (enterokinase) –0.6448 0.0000
Varia
DERL3 Der1-like domain family, Derlin-3 –0.3761 0.0088
ECE2* endothelin converting enzyme 2 –0.4110 0.0009
ITGA2 integrin alpha 2 –0.3717 0.0314
ORM2* Orosomucoid 2 –0.3725 0.0323
TERT telomerse reverse transciptase (telomere maintenance) –0.3387 0.0307
YIPF3* Yip1 domain family, member 3 –0.4741 0.0002
PSME2* proteasome activator subunit 2 –0.3550 0.0144
1Asterisk: presence of the TEAD binding sites in gene promoters. Paragraph:  genes involved in stem cell activation.
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Recent studies showed that Hippo/Yap signaling 
controls the epithelial progenitor cell proliferation and 
differentiation [31]. Our observations clearly show a link 
between the overexpression of YAP1 and the acquisition of 
some stem cell properties by HCC. Specifically: (a) both 
YAP1 and CD133, NANOG and OCT-3/4 stem cell markers 
are overexpressed in HCC, and their expression is higher 
in more aggressive tumors exhibiting higher growth rate 
and lower apoptosis; (b) NANOG and OCT-3/4 protein 
levels are statistically correlated with YAP1 and YAP1-
TEAD levels in HCC; (c) forced YAP1 overexpression 
in liver tumor cell lines induces consistent increase of 
Figure 8: Effect of YAP1 forced overexpression on the viability and expression of CD133, NANOG and OCT3-3/4 of 
human Hep3b, Huh7, and HepG2 liver cancer cells. The cells were transiently transfected with YAP1 cDNA in pCMV6 vector. Cell 
viability, and gene expression were determined in untransfected cells (C) or 48 h after transfection with empty vector (V) or 400 ng of YAP1 
cDNA. Data are means (SD) of three independent experiments of N-fold differences in mRNA expression relative to the RNR-18 expression, 
and named N Target (NT) = 2-ΔCt; ΔCt = Ct RNR18-Ct target gene. Mann-Whitney test. Viability: Point, different from C; asterisk, different 
from V for P < 0.001. Gene expression: Point different from C for at least P < 0.01; asterisk, different from V for  P < 0.001.
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CD133, NANOG and OCT-3/4 expression, cell viability, 
migration and invasivity, whereas YAP1 inhibition by 
specific siRNA leads to opposite changes; (d) stem cell 
markers overexpression does not occur in cancer cell 
lines transfected with mutant YAP1 that does not form 
complexes with TEAD [23]. Remarkably, microarray 
analysis showed that forced YAP1 overexpression in Huh7 
cells resulted in increased expression of genes that mediate 
the acquisition of a stem cells phenotype in cancer of liver 
and/or other tissues, including MAP2K5 [32, 33], PPM1A 
[34], PTPN11 [35], PTPRM [36], PDE2A [37] IRF2 [38], 
LDHA [39] SH3KBP1 [40] and SPSB1 [41]. Interestingly, 
the expression of MAP2K5, PPM1A, PTPN11, and SPSB1 
revealed a sharp increase especially in more aggressive 
HCCP exhibiting highest expression of stem cell markers, 
as well as in HepG2 cells transfected with YAP1. Taken 
Figure 9: Analysis of the effect of YAP1 inhibition by specific siRNA on the viability and expression of CD133, NANOG 
and OCT3-3/4 of human Hep3b, Huh7, and HepG2 liver cancer cells. The cells were transfected with RNAIRNT (R) or 
50  nmol/L of YAP1 siRNA. Cell viability, and gene expression were determined in untransfected cells (C) or 48 h after transfection. Data 
are means (SD) of three independent experiments of N-fold differences in mRNA expression relative to the RNR-18 expression, and named 
N Target (NT) = 2-ΔCt; ΔCt = Ct RNR18-Ct target gene. Mann-Whitney test. Viability: Point, different from C; asterisk, different from R for 
P < 0.001. Gene expression: Point different from C for at least P < 0.01; asterisk, different from R for  P < 0.001.
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Figure 10: Analysis of the effect of YAP1 inhibition by specific siRNA or forced overexpression on the expression of 
NANOG protein in human Hep3b liver cancer cells. The cells were transfected with RNAiMAX (R) or 50 nmol/L ng of YAP1 
siRNA or with 400 ng of YAP1 cDNA in pCMV6 vector (V). Gene expression was determined in untransfected cells (C) or 48 h after 
transfection. (A) Representative Western blots. Protein lysates were immunoprecipitated with specific antibodies and separated by SDS-
PAGE. (b) Chemiluminescence analysis showing means (SD) of 5 experiments. Optical densities of the peaks were normalized to β-actin 
levels and expressed in arbitrary units. Mann-Whitney test:  Point, different from R; asterisk, different from V; P < 0.001. 
Figure 11: Inhibition by YAP1 of apoptosis induced in Huh7 and HepG2 cells by oxygen peroxide. Apoptosis is expressed 
as decrease in the 36/(17+19) kD bands ratio indicating Caspase 3 cleavage. Chemiluminescence analysis: optical densities were normalized 
to β-actin levels and expressed in arbitrary units. Data are means (SD) of 3 experiments. Mann-Whitney test. Asterisks: difference from the 
appropriate vector for P < 0.001. Points: difference from YAP1/YAP1M for P < 0.001. Abbreviations: V, PCMV; VM, vector of mutated 
YAP1; YAP1M, mutated YAP1.
Oncotarget49209www.impactjournals.com/oncotarget
Figure 12: Evidence of the involvement of the YAP1-tEAD complex in the regulation of the expression of the stem cell 
markers.  (A–c) Effect of 0.5 and 2 μM verteporfin on expression of stem cell markers in Huh7 cells transfected with YAP1. (A) mRNA 
levels were determined by QRT-PCR. N Target (NT) = 2-ΔCt; ΔCt = Ct RNR18-Ct target gene. Data are means (SD) of 3 experiments. (B) 
Representative Western blots. (C) Chemiluminescence analysis showing means (SD) of 4 experiments. Optical densities of the peaks were 
normalized to β-actin levels and expressed in arbitrary units. Mann-Whitney test: YAP1 vs. V, P < 0.001, and YAP1/VP0.5/2 vs YAP1, 
P < 0.001 for all genes tested, for both quantitative RT-PCR and chemiluminescence analysis. (D–F) Expression of stem cell markers in 
Huh7 cells transfected with mutant YAP-S94A/S127A (YM). (D) mRNA levels were determined by QRT-PCR. (E) Representative Western 
blot and (F) cheliluminescence analysis showing means of 3 experiments. Optical densities of the peaks were normalized to β-actin levels 
and expressed in arbitrary units. Mann-Whitney test: YM vs. V, P < 0.001 for YAP1; not significant for all other genes. Abbreviations: C, 
control; V, empty vector; VP0.5, VP2, verteporfin 0.5 and 2 μM. YM, mutated YAP1. Vertperfin was dissolved in DMSO. Results with 
DMSO alone did not differ from C and were not included in the figure. 
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together, these findings strongly suggest that the YAP1/
TEAD complex may induce, both directly and indirectly, 
several changes leading to the acquisition of some 
stemness features by HCC cells.
Microarray analysis also revealed that forced YAP1 
overexpression transcriptionally activates a variety of 
genes involved in signal transduction and cell proliferation. 
Among them, PPM1A encodes a phosphatase that 
dephosphorylates nuclear exporter RanBP3 at ser58, thus 
stimulating nuclear exclusion of SMAD2/3 [42]. SFRS10 
[43], CAPRIN1 [44], and CEP55 [45] are implicated in 
ovarian, breast and bladder carcinogenesis, respectively. 
CSPP1 is a mitosis regulator [46]; LGALS7 [47] and 
PDE2A [48] are overexpressed in different cancer types; 
LDHA encodes one of the major glycolysis enzymes. Of 
note, glycolytic ATP production in HCC is correlated with 
tumor cell aggressiveness [1]. 
Among inhibited genes, CDC42SE2 controls the 
activity of cell division cycle protein (CDC42), which 
exhibits oncosuppressor activity [49]. HHIP encodes 
an inhibitor of the Hedgehog pathway, implicated in 
HCC pathogenesis [1, 50]. PDHA2 encodes pyruvate 
dehydrogenase. The overexpression of the E1α subunit 
of pyruvate dehydrogenase complex is apoptogenic for 
HCC cells [51].  DERL3 loss leads to SLC2A1 (glucose 
transporter 1, GLUT1) overexpression, which contributes 
to the Warburg phenomenon of tumor cells [52]. ITGA2 
inhibition is associated with non-invasive prostatic 
cancer [53] and reduced cell migration in colorectal 
cancer [54]. The TEAD consensus sequence is present 
in the promoter of several genes whose expression 
was increased or decreased in YAP1-transfected cells 
(Table 2). Surprisingly, the TERT gene, generally 
overexpressed in HCC cells [55], was inhibited in YAP1-
transfected cells. It must be considered, in this respect, 
that individual functional elements in transcriptional 
activation domains are responsible for activating specific 
cellular genes by different transcription factors, in a 
context-specific manner [56, 57]. Therefore, it may be 
hypothesized that signaling pathways different from 
Hippo/YAP signaling may prevalently regulate some 
genes, in the absence of forced YAP1 overexpression. 
Further work is necessary to clarify this apparent 
discrepancy. Overall, gene expression profiles of Huh7 
cell transfected with YAP1 strongly suggest that this 
gene may influence HCC cell growth and progression 
Figure 13: Unsupervised hierarchical cluster analysis of gene expression patterns of Huh7 cells. Microarray experiments 
with RNA from 4 independent Huh7 cell cultures, transfected with YAP1 cDNA or empty vector (V) were made. 136 gene features, 
showing more than 1.5-fold difference compared to median expression value in 4 arrays, were selected for cluster analysis. Expression 
values were Log 2 transformed before clustering. Rows represent individual genes and columns represent each tissue.
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by complex mechanisms involving numerous genes/
signaling pathways regulating the proliferation, stemness 
and aggressiveness of HCC.
In conclusion, our data indicate that YAP1 
overexpression and post-translational deregulation are 
genetically controlled and contribute to determine a 
phenotype susceptible to HCC [2] and HCC prognosis. 
Our results support a link between YAP1 overexpression 
and acquisition of a stem cell trait by HCC and the 
hypothesis [58] that YAP1 upregulation in HCC exhibits 
a critical oncogenic role in a complex signaling network 
triggering fast growth and invasiveness. 
Figure 14: Expression of MAP2K5, PTPN11, SPB1, and PPM1A in human normal liver (NL) and Hccb and HccP 
(A) and HepG2 cells transfected with YAP1 (b). mRNA levels were determined by QRT-PCR. N Target (NT) = 2-ΔCt; ΔCt = Ct 
RNR18-Ct target gene. Data are means (SD) of NT of 5 NL and 10 of each HCC subtypes and corresponding SL and of 3 independent 
experiments with HepG2 cells. Mann-Whitney test: solid tumors: Point, different from NL for P < 0.001. Asterisk, different from HCCB 
for at least P < 0.01. HepG2 cells: YAP1 vs vector, P < 0.001 for all genes tested.
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MAtErIALs AND MEtHODs
Animals and treatments 
F344 and BN rats (Charles-River-Italia, Calco, Italy) 
were fed, housed, and treated according to the ‘‘resistant 
hepatocyte’’ protocol [59], consisting of a 150-mg/
kg intraperitoneal dose of diethylnitrosamine followed 
by 15 days of feeding a 0.02% 2-acetylaminofluorene-
containing hyperprotein diet, with a partial hepatectomy 
at the midpoint of this feeding regime. Preneoplastic 
liver (6 weeks after initiation), early dysplastic nodules 
(15 weeks) and late dysplastic nodules (32 weeks), and 
HCCs (57–60 weeks) were used. Animals received 
human care, and study protocols were in compliance 
with the National Institutes of Health guidelines for 
use of laboratory animals. Rats were killed by bleeding 
through thoracic aorta, under metedomidine anesthesia. 
Freshly removed livers were serially sectioned with 
〜0.5 cm intervals. Fifteen and 32 weeks after initiation, 
dysplastic nodules macroscopically identified by their 
sharp grayish-white color, were scooped out from the 
liver, free of surrounding parenchyma (as verified by 
histological control). HCCs were collected from F344 
and BN rats leaving out a small rim of neoplastic tissue. 
Only DNs with diameter ≧ 0.03 cm3 were collected 
from both rat strains and split in half. One half of this 
material was processed for histology, histochemistry, and 
immunohistochemistry, and the other half was stored at 
–80°C. Histological (HE staining), histochemical (silver 
staining of reticulin) and immunohistochemical (glutamine 
synthase immunostaining) criteria were used, in addition 
to morphology, to classify liver lesions according to the 
published criteria [60–62], (data not shown). 
Human tissue samples 
Six normal livers, 20 HCCP and 20, HCCB and 
corresponding surrounding non-tumor livers were used. 
Patients’ clinicopathological features are shown in Table 1. 
Liver tissues were archival samples kindly provided by 
the Department of Surgery “Pietro Valdoni”, University 
of Rome “La Sapienza”, and the Department of Surgery, 
University of Sassari. Informed patients’ consent and 
Institutional Review Board approval was obtained at these 
Departments.
cell lines and treatments
Certified HepG2 human hepatoblastoma, Hep3B 
and HuH7 human HCC cell lines were obtained 
from ATCC and maintained as monolayer cultures in 
Dulbecco’s modified Eagle medium containing 10% 
FBS, at 37°C. A total of 0.8 × 106 cells were seeded in 
6 cm dishes and transfected with small interfering RNA 
(siRNA) duplexes specific to human YAP1. siRNA and 
scramble oligonucleotide   (final concentration 50 nmol/L) 
were transfected using the RNAiMax, Invitrogene kit 
(Life technology, CA, USA). For transient transfection 
experiments, HepG2, Hep3B, and Huh7 cell lines 
were seeded and incubated 24 h before transfecting 
with pCMV6_YAP1 (400 ng of YAP1 cDNA), mutant 
YAPS127AS94A [23] (a kind gift Dr. Xin Chen, 
University of California, San Francisco), or pCAMV6-
empty Vectors (Origene, Rockville, MD, USA) by 
lipofectamine 2000 Reagent (Life technologies Corp.) 
according to manufacturer’s protocol. When indicated, 
verteporfin (0.5 or 2 μM in DMSO) or DMSO were added 
to the reaction mixture used for YAP1 transfection. For 
induction of apoptosis, H2O2 was added to cell cultures, 
at 200 and 400 μM final concentrations, 6 hour after 
transfection with YAP1. After 24 h incubation, Caspase 3 
cleavage was determined by immunoblotting as a measure 
of apoptosis and expressed as decrease in the ratio 36/
(19 + 17) kD bands.
Proliferation and viability indices 
Proliferation and progression indices were 
evaluated in human HCC by determining Ki-67 and 
MDK expression, respectively. Cell viability of liver 
tumor cell lines was determined by MTT test (Sigma, 
St. Louis, USA). For wound-healing assay with YAP1-
transfected cells, Huh7 cells were seeded into 6-well 
plates and cultured to confluence. Cells monolayers were 
then wounded with sterile pipette tips and washed with 
PBS. Pictures were acquired at the times indicated using a 
fluorescence microscope. Cell invasivity was analyzed by 
the Cytoselect 24-well cell invasion kit (Cell Biolabs, San 
Diego, USA), with 50.000 Huh7 cells/well.
Quantitative real-time rt-Pcr 
Real-Time was performed on cDNA obtained 
accordingly to High Capacity c-DNA Reverse 
Transcription Kit (Applied BioSystem, CA, USA). PCR 
reactions were performed with 75–300 ng of cDNA, using 
an ABI Prism 7500 and Quantitect SYBR Green PCR kit 
& Quantitexct Primer Assay (Qiagen Gmbh,  Hilden, 
Germany), as published [63]. 
Western blot analysis
Hepatic tissue samples and cell suspensions from 
cultured cancer cells were homogenized in lysis buffer 
[30 mM Tris (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% 
Na deoxycholate, 0.1% SDS, 10% glycerol, and 2 mM 
EDTA] containing the Complete Protease Inhibitor 
Cocktail (Roche Molecular Biochemicals, Indianapolis, 
IN) and sonicated. Protein concentrations were determined 
with the Lowry-Folin assay (Sigma, St. Louis, USA) 
using bovine serum albumin as standard. Proteins were 
cleaned by binding G-sepharose beads & IgG normal 
control (rabbit, goat & mouse). For determination of 
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YAP1-14-3-3 and YAP1-TEAD complexes, proteins 
were immunoprecipitated by YAP-goat antibody and 
western blot was performed using 14-3–3 or TEAD1 
primary rabbit antibodies. Membranes were probed 
with the antibodies shown in Table 3 and processed 
as reported [61]. Each primary antibody was followed 
by incubation with horseradish peroxidase-secondary 
antibody diluted 1:5000 for 1 h and then revealed with the 
Super Signal West Pico Chemiluminescence Substrate Kit 
(Pierce Chemical Co., New York, NY). For each protein, 
densities were calculated by ImageQuaNT 5.1 software 
(GE Healthcare, Piscataway, NJ), normalized to β-Actin 
(Santa Cruz Biotechnology, Santa Cruz, CA; dilution 
1:10000) levels, and mean values evaluated for statistical 
significance..
Microarray analysis
High-quality RNA from 4 independent Huh7 cell 
cultures transfected with 400 ng of YAP1 cDNA and 4 
control cell lines transfected with vector alone, were used 
to obtain fluorescently labeled complementary double-
stranded DNA (cDNA). cDNA was labeled with Cy3 or 
Cy5, hybridized using Agilent In situ Hybridization Kit-
plus (Agilent Technologies, Wilmington, DE). Microarray 
experiments were made with Agilent Human G4131F 
4 × 44 K. Fluorescence intensities were measured using 
ImaGene 8.0 software and analyzed by Nexus Expression 
software (Biodiscovery, El Segundo, CA). To select 
the spot subsets, we followed the criterion of minimum 
variance in quadruplicate fluorescence ratio measurements, 
when the fluorescence signal was higher than 0.3% of the 
measurable total signal dynamics range above background 
in both channels of the hybridization. For normalization, 
the intensity of each spot was divided by average intensity 
of housekeeping genes. Genes showing more than 1.5- fold 
difference compared to median expression value in more 
than 4 arrays, were selected for cluster analysis. The 
algorithm based on Pearson correlation coefficients was 
used for hierarchical cluster analysis. K-mean clustering 
analysis, and visualization of analyzed data were 
performed as described [64]. 
statistical analysis
Data are expressed as means ± SD. GraphPad 
Prism 5.01 (www.graphpad.com) was used to evaluate, 
by Tukey-Kramer test, the significance of differences 
between means of QPCR and Western blot analyses of 
rat samples, and calculate the correlation coefficient (R) 
by multiple regression analysis. The expression of human 
HCC subgroups were evaluated by the Mann-Whitney 
U-test. Statistical analysis of microarray results was 
performed by parametric Student’s t-test and the False 
Discovery Rate (FDR) method to correct P-values and 
control false identifications, using the BRB Array Tools 
(http://linus.nci.nih.gov/BRB-Array.Tools.htlm). Values of 
P < 0.05 were considered significant.
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table 3: Antibodies used for immunoprecipitation and Wester analyses
Antibody species  (Antibody titres) company Immunogen
OCT-3/4 (A-9) Mouse (1:50) Santa Cruz; 365509 a.a 16-45 near the N-terminus
NANOG (1E6C4) Mouse (1:100) Santa Cruz; 293121 a.a 20-166
PAN-TEAD  Rabbit (1:1000) Cell Signaling; 8526 D3F7L
CD133/1 Mouse (1:150) Macs; W6B3C1 Clone W6B3C1
YAP Mouse (1:400) Abnova; H00010413-M01 53 a.a~161 a.a
YAP (C-20) Goat Santa Cruz; 17141 C-20 peptide Near the C-terminus of Yap
p-YAP S127 Rabbit (1:1000) Cell Signaling; 4911 Ser 127
p-YAP Y357 Rabbit (1ug/ml) Abcam; AB62751 Tyr357 in C-terminal amino acids 351-362 of Human YAP1
CASPASI 3 Rabbit (1:1000) Cell Signaling; 9662 KLH peptide corresponding to residues surrounding the cleavage site of caspase3
p-p73 y99 Rabbit (1:1000) Abcam; AB38457 Tyr 99
14-3-3 σ  Mouse (1:300) Santa Cruz; 166473 E-11 epitope mapping between a.a 8-38 at the N-terminus of 14-3-3
Ub (P4D1) Mouse (1:500) Santa Cruz; 8017 a.a 1-76 representing full lenght Ub
CTGF Rabbit (1:500) Abcam; 5097 Residues 150-250
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